First Asian launch for ulipristal, in South Korea
This article was originally published in Scrip
HRA Pharma has launched the emergency oral contraceptive ellaOne (ulipristal acetate) in South Korea through its licensee for this market, Hyundai Pharm.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.